Epigenetic therapies for chemoresensitization of epithelial ovarian cancer
DE Matei, KP Nephew - Gynecologic oncology, 2010 - Elsevier
DE Matei, KP Nephew
Gynecologic oncology, 2010•ElsevierEpigenetic drugs have been shown to enhance gene expression and drug sensitivity in
ovarian cancer cell lines and animal models. Based on promising preclinical studies, DNA
methylation inhibitors in combination with existing chemotherapeutic agents have the
potential for overcoming acquired drug resistance, laying the foundation for this specific
class of epigenetic drug in ovarian cancer clinical trials. The recent completion of phase I
trials of decitabine has yielded important information on dosing schedules and biological …
ovarian cancer cell lines and animal models. Based on promising preclinical studies, DNA
methylation inhibitors in combination with existing chemotherapeutic agents have the
potential for overcoming acquired drug resistance, laying the foundation for this specific
class of epigenetic drug in ovarian cancer clinical trials. The recent completion of phase I
trials of decitabine has yielded important information on dosing schedules and biological …
Epigenetic drugs have been shown to enhance gene expression and drug sensitivity in ovarian cancer cell lines and animal models. Based on promising preclinical studies, DNA methylation inhibitors in combination with existing chemotherapeutic agents have the potential for overcoming acquired drug resistance, laying the foundation for this specific class of epigenetic drug in ovarian cancer clinical trials. The recent completion of phase I trials of decitabine has yielded important information on dosing schedules and biological endpoints for evaluating patient responses. In addition, epigenetic drug effects on pharmacodyamic targets are beginning to emerge, and predictive epigenetic biomarkers and next generation epigenome therapeutics are being developed for application in clinical settings for ovarian cancer patients.
Elsevier